Table 4 Results of content uniformity testing of OLZ and DZP tablets by the suggested method
Parameter | Tablet no. | % of the labeled claim | ||
|---|---|---|---|---|
OLZ | DZP | |||
Prexal® (5 mg/tablet) | Olapex® (5 mg/tablet) | Neuril® (5 mg/tablet) | ||
% recovery | % recovery | % recovery | ||
| Â | 1 | 101.40 | 102.90 | 100.98 |
2 | 100.15 | 99.80 | 100.00 | |
3 | 103.90 | 98.50 | 101.74 | |
4 | 100.00 | 100.26 | 103.30 | |
5 | 100.98 | 100.14 | 99.70 | |
6 | 100.90 | 101.86 | 102.46 | |
7 | 103.70 | 97.09 | 101.40 | |
8 | 101.00 | 98.46 | 101.00 | |
9 | 98.00 | 101.95 | 102.74 | |
10 | 98.19 | 101.77 | 97.50 | |
Mean | Â | 100.82 | 100.27 | 101.08 |
S.D | 1.95 | 1.86 | 1.70 | |
% RSD | 1.933 | 1.859 | 1.683 | |
% error | 0.62 | 0.59 | 0.76 | |
Acceptance value (AV) | 4.68 | 4.47 | 4.08 | |
Maximum allowed AV (L1) | 15.0 | 15.0 | 15.0 | |